A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese Participants

The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.

开始日期2022-11-11

申办/合作机构

Eli Lilly & Co.

NCT05377333 / Completed临床1期

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.

开始日期2022-06-02

申办/合作机构

Eli Lilly & Co.

NCT05110664 / Unknown statusN/AIIT

A Double-blind, Cross-over, Placebo-controlled, Proof-of-concept Study Using Oral Peptide YY3-36 Solution to Investigate the Mechanistic Role of Lingual PYY in Regulating Appetite, Energy Intake and Food Preference in People With Overweight/Obesity

A double-blind, cross-over, placebo-controlled, proof-of-concept study using oral peptide YY3-36 solution to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity. The aim of this study is to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity.

开始日期2022-02-01

申办/合作机构

University College London

[+1]

100 项与 NPY receptor 相关的临床结果

登录后查看更多信息

100 项与 NPY receptor 相关的转化医学

登录后查看更多信息

0 项与 NPY receptor 相关的专利（医药）

登录后查看更多信息

3,156

项与 NPY receptor 相关的文献（医药）

2024-12-01·Computers in Biology and Medicine

Bioinformatic analysis of neuropeptide related genes in patients diagnosed with invasive breast carcinoma

Article

作者: Ayan, Durmus ; Yay, Fatih

PURPOSENeuropeptide receptors are expressed in many malignancies. Effectors involved in the action mechanisms of HCRTR1, HCRTR2, NPY4R (PPYR1) may be related to breast cancer (BC). Genes encoding these receptors and PPY and PTPN11 genes were aimed to examine via bioinformatics tools in the BRCA cohort. To our knowledge, this is the first study in which these receptor genes and PP, which have not found much research in BC, are examined together with PTPN11 and analyzed comprehensively in large patient cohorts from public databases.METHODScBioPortal was used for gene alteration analyses, GeneMania for association analyses with other genes, Kaplan-Meier Plotter for Overall Survival (OS) and Relapse Free Survival (RFS) analyses, UALCAN for methylation analyses, TIMER2.0 for expression analyses, The Human Protein Atlas database for expression validations, TIMER for immune infiltration analyses, WEKA 3.8.6 for diagnostic classification performances of the genes based on Random Forest Classifier and Enrichr-KG for Gene Ontology (GO) Biological Process (BP) and KEGG analysis.RESULTS19 (1.9 %) nucleotide changes were found in 996 cases. Missense mutation is most common. Decreased expression levels of the HCRTR1 gene were associated with shorter OS and RFS, but decreased expression levels of the PTPN11 gene were associated with longer OS and RFS. Decreased expression levels NPY4R (PPYR1) gene were associated with shorter RFS. Increased expression levels of HCRTR2 and PPY genes were associated with longer RFS. HCRTR1 and NPY4R (PPYR1) genes were statistically hypermethylated; conversely HCRTR2 and PPY genes were hypomethylated. There was no significant change in PTPN11 gene promoter methylation level. HCRTR1, NPY4R (PPYR1) and PTPN11 gene expressions were downregulated; conversely, HCRTR2 and PPY gene expressions upregulated. Weak correlations were observed between NPY4R (PPYR1) gene expression and CD4⁺ T Cell, Neutrophil, Dendritic Cell and between PTPN11 gene expression and CD8⁺ T Cell, Macrophage, Neutrophil, Dendritic Cell infiltrations. Area under the receiver operating characteristics curve values of the 10-fold cross-validation and by splitting the dataset in a ratio of 80:20 models were 0.930 and 0.963 respectively. HCRTR2 and HCRTR1 belong to regulation of cytosolic calcium ion concentration, cellular calcium ion homeostasis GO BPs.CONCLUSIONIn BC patients, increases in HCRTR2 and PPY gene expressions could be considered as positive prognostic factors. Decreases in HCRTR1 and NPY4R (PPYR1) gene expressions could be considered as negative prognostic factors. Decreased expression of PTPN11 gene may have a positive prognostic factor. Changes in existing genes are likely to be both a biomarker and therapeutic target for BC. However, experimental and clinical studies are needed to elucidate the mechanisms underlying these neuropeptide receptors in terms of breast carcinogenesis.

2024-12-01·Molecular and Cellular Endocrinology

The adipose tissue melanocortin 3 receptor is targeted by ghrelin and leptin and may be a therapeutic target in obesity

Article

作者: Rosendo-Silva, Daniela ; Abrantes, Ana Margarida ; Eickhoff, Hans ; Seiça, Raquel ; Botelho, Maria Filomena ; Lopes, Eduardo ; Viana, Sofia ; Reis, Flávio ; Monteiro-Alfredo, Tamaeh ; Falcão-Pires, Inês ; Pires, Ana Salomé ; Matafome, Paulo

OBJECTIVEObesity is linked to perturbations in energy balance mechanisms, including ghrelin and leptin actions at the hypothalamic circuitry of neuropeptide Y (NPY) and melanocortin. However, information about the regulation of this system in the periphery is still scarce. Our objective was to study the regulation of the NPY/melanocortin system in the adipose tissue (AT) and evaluate its therapeutic potential for obesity and type 2 diabetes.METHODSThe expression of the NPY/melanocortin receptors' levels was assessed in the visceral AT of individuals with obesity and altered metabolism. Protein levels of these receptors were evaluated in cultured adipocytes incubated with ghrelin (30 and 100 ng/mL) and leptin (1 and 10 nM) and in the AT of an animal model with a mutation in the leptin receptor (ZSF1 rat), to understand their regulation by leptin and ghrelin. The vertical sleeve gastrectomy animal model was used to evaluate the putative therapeutic potential of the NPY/melanocortin system.RESULTSIn this study, we unravelled that leptin (1 nM and 10 nM) selectively reduced the levels of NPY5R and MC3R but no other NPYR/MCRs in cultured adipocytes. In turn, acylated ghrelin (100 ng/mL) significantly increased NPY1R, but the inhibition of its receptor also abrogates MC3R levels. However, in the Lepr-deficient ZSF1 rat, both NPY5R and MC3R levels were reduced, along with other NPYRs and MCRs, suggesting that leptin resistance negatively affects NPY and melanocortin signalling. In human adipose tissue, we found a downregulation of genes encoding the NPY and melanocortin receptors in the visceral AT of individuals with obesity and insulin resistance, being correlated with genes regulating metabolic activity. Additionally, diabetic obese rats submitted to vertical sleeve gastrectomy showed increased levels of NPY, melanocortin, ghrelin, and leptin receptors in the AT, including MC3R, suggesting it may constitute a therapeutic target in obesity.CONCLUSIONSOur results suggest that the AT NPY/melanocortin system, particularly the MC3R, may be involved in the neuroendocrine regulation of adipocyte metabolism. Altogether, our work shows MC3R is under the control of the ghrelin/leptin duo, is reduced in patients with obesity and prediabetes, and may constitute a therapeutic target in obesity.

2024-12-01·Neuropeptides

Phosphorylated NPY1R regulates phenotypic transition of vascular smooth muscle cells, inflammatory response and macrophage infiltration to promote intracranial aneurysm progression

Article

作者: Tang, Ting ; Wang, Tao ; Jiang, Yuanding ; Liang, Richu ; Duan, Yonghong ; He, Jian ; Luo, Jie

BACKGROUNDRupture of intracranial aneurysm (IA) could give rise to spontaneous subarachnoid hemorrhage, leading to a high disability rate and even death. NPY1R expression was upregulated in aneurysm tissues of IA patients. However, the role and underlying mechanism of NPY1R remains unknown.METHODSThe IA model of mice was established using inducing systemic hypertension and injecting elastase. The expression of genes and proteins was detected by RT-qPCR and western blot. The number of T cells, macrophages, and neutrophils in IA mice was detected using flow cytometry and IF assay. The levels of inflammatory factors were measured using ELISA. Patho-morphology and inflammatory cells in aneurysm tissues were evaluated by HE staining. The interaction between TK and NPY1R was validated using Co-IP.RESULTSNPY1R expression was greatly elevated in aneurysm tissues in IA patients and mice, which were positively related to macrophage infiltration. Besides, exogenous overexpression of NPY1R resulted in the promotion of contractile phenotype to the synthetic phenotype of vascular smooth muscle cells (VSMCs), inflammatory response and M1 macrophage polarization. In terms of the underlying mechanism, NPY1R protein could be modified by TK-mediated phosphorylation and TKI could decrease IA formation and suppresse contractile phenotype to synthetic phenotype of VSMCs, inflammatory response and M1 macrophage polarization in IA mice. Furthermore, ablating mouse macrophages abolished NPY1R overexpression-mediated promotion of IA formation and rupture in mice.CONCLUSIONPhosphorylated NPY1R contributed to IA progression through promoting contractile phenotype to synthetic phenotype of VSMCs, inflammatory response and M1 macrophage polarization in IA.

项与 NPY receptor 相关的新闻（医药）

2024-10-08

·研发客

年入107亿美元，恩格列净上市10年仍在放量｜光影

// • 获批心血管相关适应症的次年，全球营收突破10亿美元； • 获批心衰适应症后，全球营收增长在2021年和2022年均超过20亿美元； • 去年又获批慢性肾病适应症，凭借“糖心肾”三重获益强势破圈。 “百亿美元分子系列”回顾 Genmab营收主力Darzalex，能否成为百亿美元分子？ 130亿欧元闯关，Dupixent接棒自免“新王”？当司美格鲁肽“大杀四方”时，代谢领域另一位强者正强势崛起。根据礼来和勃林格殷格翰（BI）2023年财报，恩格列净（欧唐静，Jardiance）去年全球销售额增长31%至107亿美元以上，首次突破百亿美元大关。在上市时间落后于阿斯利康达格列净和强生卡格列净的情况下，恩格列净不仅实现后来居上，而且上市10年仍在持续放量。同为钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，恩格列净凭什么破圈？始于降糖最初，恩格列净被BI开发用于2型糖尿病治疗。2011年，BI与礼来达成合作以开发多种类型的降糖药，其中就包括这款产品。 2014年，恩格列净相继在欧洲和美国获批。彼时，降糖市场早已“人才济济”，不仅有历史悠久的胰岛素、神药二甲双胍，更有α-糖苷酶抑制剂、GLP-1、DPP-4等降糖药。不过与大多数降糖药不同，SGLT2抑制剂的降糖机制不依赖于胰岛素作用，而是通过抑制肾小管葡萄糖重吸收的关键蛋白——SGLT2来发挥作用。SGLT2能重吸收90%的葡萄糖，其功能抑制后可让更多糖分从尿液中排出。正是凭借这种独特的作用机制，SGLT2抑制剂诞生后就一跃成为降糖市场的后起之秀。不过早期的恩格列净由于上市时间晚，其全球营收明显落后于竞品卡格列净和达格列净。转机出现在2016年底。 2016年底，恩格列净在EMPA-REG OUTCOME试验中被证实可将心血管疾病死亡风险降低38%。基于此，FDA又批准该药用于降低2型糖尿病合并心血管疾病患者的心血管死亡风险。FDA曾在新闻稿中表示，心血管疾病是2型糖尿病成人患者死亡的主要原因，通过降低心血管死亡风险来帮助人们延长寿命是降糖疗法的一个重要进步。作为首个获批用于降低心血管死亡风险的2型糖尿病药物，次年恩格列净全球营收便大幅增长135.7%，并首次突破10亿美元大关。此后，恩格列净一路保持良好的增长势头，并于2018年以近24亿美元坐上SGLT2抑制剂市场的头把交椅。成于跨界在EMPA-REG OUTCOME试验结果中，研究人员还敏锐地察觉到，恩格列净可能带来另一个意外之喜——心衰获益。拓展阅读从尿糖开始的糖尿病居然能通过尿糖来治疗？不过，由于该试验入组的均为2型糖尿病患者，难以充分论证该药在慢性心衰治疗中的确切疗效，于是就有了2017年启动的两项大型3期对照研究——EMPEROR-Reduced和EMPEROR-Preserved。结果不负众望。在3730例射血分数降低型心力衰竭（HFrEF）受试者中，恩格列净将心血管死亡或因心衰而住院构成的复合终点风险降低25%；在5988例射血分数保留型心力衰竭（HFpEF）受试者中，恩格列净将心血管死亡或因心衰而住院的相对风险降低21%。基于此，恩格列净于2021年8月获得FDA批准扩展适应症，用于在HFrEF成人患者中降低心血管死亡和住院风险，成为首个获批用于治疗心衰的SGLT2抑制剂。一年后，该药再获FDA批准，用于治疗有症状的慢性心力衰竭成人患者，成为首个获批治疗所有心衰类型的疗法。至此，恩格列净成功跳出糖圈，并迅速席卷心内科市场。它不仅让HFrEF的治疗思路从传统“金三角”向“新四联”转变，而且成功挑战了慢性心衰的分类模式，患者无论左心室射血分数（LVEF）如何，均能从恩格列净治疗中受益。数据显示，心衰与极高的发病率、死亡率相关，累及全球超6000万人。恩格列净获批心衰适应症后，全球营收增长在2021年和2022年均超过20亿美元。不过恩格列净并未止步于此。心衰之后，该药又在治疗慢性肾病试验（EMPA-kidney）中证明可将患者肾病进展或心血管死亡的相对风险降低28%。2023年，恩格列净先后在欧盟和美国获批用于治疗慢性肾病成年患者，这是一种影响全球近8.5亿人的疾病。同年，它还在全球多地被批准用于治疗10岁及以上儿童2型糖尿病。这些新适应症不仅推动恩格列净跻身百亿美元分子行列，未来几年或将成为该药新的增长点，直到2028年欧美地区专利到期。值得一提的是，恩格列净在中国市场由于专利无效早已进入仿制药和集采时代。 “心-肾-代谢”新篇章根据BI官网公示的产品管线，该公司还在探索恩格列净与醛固酮合成酶抑制剂BI 690517联合用药的效果。此前，该联合疗法已在治疗慢性肾病患者的2期试验中取得积极结果。数据显示，两药联用可显著减少患者蛋白尿水平，这些改善可能导致与肾脏疾病相关临床事件的风险降低至少30%。 ClinicalTrials官网显示，BI还在开展一项3期EASi HF试验，以评估恩格列净与BI 690517联合使用在症状性心力衰竭和LVEF≥40%的受试者中的疗效和安全性。实际上，心血管、肾脏和代谢系统相互关联。这组疾病影响全球超过14亿人，是导致死亡的主要原因。2023年10月，美国心脏协会（AHA）首次明确提出心血管-肾脏-代谢（CKM）综合征的概念。从近年发布的ADA、AACE、CDS等国内外指南也可以看出，“心-肾-代谢”共管已成为大势所趋。拓展阅读降糖、减重、代谢药物试验设计新思路在此背景下，BI除了押宝恩格列净，还在继续开拓“心-肾-代谢”管线。比如处于3期临床阶段的GLP-1R/GIPR 双重激动剂survodutide（BI 456906），拟用于肥胖、代谢功能障碍相关性脂肪性肝炎；处于2期阶段的心脏病调节剂BI 765845，以及拟用于肾小球硬化的TRPC6抑制剂BI 764198；处于1期阶段的GLP-1/FGF21双重激动剂、抗纤维化药物和NPY2r激动剂等。编辑 | 姚嘉 yao.jia@PharmaDJ.com 总第2217期访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com

财报

2024-07-30

·Business Wire

CinFina Pharma Announces Initiation of Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of CIN-110 for the Treatment of Obesity

CINCINNATI--( BUSINESS WIRE )--CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the initiation of the Phase 1 MAD clinical trial for CIN-110, a novel, highly selective PYY 3-36 analog for the treatment of obesity. This Phase 1 MAD clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in adults with obesity. The initiation of this MAD trial follows the ongoing SAD study, where CIN-110 was well-tolerated with noteworthy reductions in caloric intake and body weight. The SAD study will be used to inform dosing decisions in the current MAD study. “ To date, CIN-110 has demonstrated very strong safety and pharmacokinetic profiles in its single dose study, as well as encouraging pharmacodynamic data,” said Mary Bond, M.S., M.B.A., Chief Translational Science Officer of CinRx Pharma. “ We are excited to see this promising asset advance into this next clinical assessment where we will gain an even greater understanding of its potential to provide a safe and effective obesity treatment option for physicians and their patients.” As a potent and highly selective PYY 3-36 analog with an extended half-life, CIN-110 has the potential to be durable and well-tolerated without the significant nausea and emesis seen in previous attempts to develop PYY-focused therapies. PYY 3-36 is an endogenous hormone secreted from endocrine L-cells in the gut in response to food, particularly fat ingestion, acting as a selective agonist of the neuropeptide Y2 receptor (Y2R) and safely decreasing food intake by reducing appetite. About CIN-110 Phase 1 MAD Study: The multiple ascending dose (MAD) study is designed as a randomized, placebo-controlled clinical trial that will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 delivered subcutaneously (SC) in study subjects with obesity over 12 weeks. Trial participants are males and females, ages 18-55, with a body mass index between 30.0 and 44.9 kg/m2. The study is planned to include multiple cohorts, each with 12 subjects randomized in a 3:1 ratio to receive SC CIN-110 or a matched placebo, respectively. About CinFina Pharma: CinFina Pharma, a CinRx portfolio company, is expanding the treatment options for obesity and its associated comorbidities with a pipeline of therapeutic candidates designed to be safe, tolerable and durable to help people lose weight and keep it off to improve their overall health. CinFina’s four therapeutic candidates are naturally occurring peptides engineered for prolonged activity which send signals in the body to control insulin secretion or feelings of satiety. Learn more at www.CinFina.com . About CinRx Pharma: CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio. For more information, please visit www.CinRx.com or follow the company on X and LinkedIn .

临床1期

2024-07-02

·药通社

脑卒中“一哥”丁苯酞或遇下一代王者

2024 CMC（CRO&MAH&CMO）博览会，将于8月15-16日在苏州国际博览中心C、D、E馆召开，内容涵盖前沿法规政策、MAH、改良型新药、吸入制剂、透皮制剂、中药、缓控释制剂、注射剂、原料药、辅料领域热点话题。仿制药立项思路和产品布局如今有何变化？以透皮给药平台为导向的产品立项思路如何？一键报名 · 见证合作！最近，脑卒中领域研发“先驱”南京宁丹再发重磅信息： 2024年6月27日，他们首次在CDE网站公示了注射用Y-3治疗急性缺血性卒中的三期临床研究情况。根据公开资料，ZL006-05（即Y-3）公开了结构式，很明显是两个片段成脂键的前药设计，再看看右边那个片段，有点似曾相识，没错，就是那个游离在中药和化药之间的分子：右莰醇（天然冰片）！谈到右莰醇，业内首先会想起先声药业的当家花旦：依达拉奉右莰醇小水针。南京宁丹与先声药业有着千丝万缕的关系。先声药业目前在研的依达拉奉右莰醇舌下片就是由南京宁丹合作研发的。竞争格局目前治疗脑卒中的销量扛把子产品是丁苯酞，哪怕是诊疗指南金标准药物溶栓类也望尘莫及！偌大的市场被石药集团独占。图 | 丁苯酞制剂年销量图源 | 药融云数据库先声药业面对如此巨大的市场，也早已开始了布局。对于同样对脑卒中有治疗效果的依达拉奉+右莰醇制剂，其中依达拉奉右莰醇注射用浓溶液20年就已获批上市，依达拉奉右莰醇舌下片于2023进行了申报。图 | 依达拉奉右莰醇注射用浓溶液年销量图源 | 药融云数据库届时先声药业预计将掌握依达拉奉右莰醇的两种剂型，市场格局将会有变革。目前依达拉奉右莰醇的两个剂型的三期临床试验文章均已发表，小水针第90天脑卒中mRS评分0~1分比例67.1% vs 59.0%，舌下片65% vs 54%。基于如此主观的量表，两个临床研究打出的分数是相当的漂亮，非常符合逻辑，如果把疗效从绝对数值排序（当然这样是很不严谨的，但是又会本能的这样去看）：依达拉奉右莰醇小水针＞依达拉奉右莰醇舌下片＞依达拉奉＞安慰剂这个成绩，无论是给投资人看还是学术推广，都堪称perfect！依达拉奉右莰醇的市场容量目前虽未达到丁苯酞的水平，但若孪生兄弟：依达拉奉右莰醇舌下片（Y-2）的批准上市，再由先声药业相当成熟的神经系统商业化团队推广，两种剂型双管齐下，中国脑卒中药物“一哥”丁苯酞表示压力很大！进一步布局基于以上两个三期临床试验也能得出一个结论：右莰醇增强疗效的作用是基本坐实了。故而想到将其接到另一个靶点药物上去申请核心化合物专利便也水到渠成，就有了开篇提到的Y-3。根据公开信息报道，Y-3的另外一个片段是靶向PSD-95，与国外正在三期临床试验中的药物Nerinetide同靶点，该药物一项三期临床研究ESCAPE-NA1显示其在非溶栓患者中疗效与安慰剂有显著差异，给了PSD-95靶点一线希望，但遗憾的是2023年公布的第二项三期临床研究ESCAPE-NEXT显示未优效于安慰剂。而背靠专业脑保护玩家先声药业的南京宁丹新药，前有双剂型的临床运营成功经验，后有右莰醇的功效继续加持，对Y-3的靶向研究势在必得。也正是看到依达拉奉右莰醇小水针运作如此成功，若新拥有这样一个神经保护剂，就相当于拥有了一台印钞机。康哲药业甚至都没有等到Y-3二期临床试验结果出来，就立马买下其中国的独家商业化推广权，外加股权投资。最后笔者大胆猜测：通过南京宁丹新药公开的研发管线资料和专利申请，公司专注于舌下给药技术和复方多靶点设计，除Y-2（依达拉奉右莰醇组合物）和Y-3（含右莰醇片段）外，Y-4、Y-5、Y-6和Y-8有可能都含有右莰醇或片段，成为超越丁苯酞的下一代王者。【题外话】笔者一直有个疑问：为什么脑保护剂国外做一个死一个，先声/宁丹/益诺依为什么做一个成一个？明明国内入组的脑卒中患者严重程度（NIHSS评分）更低（安慰剂效应更强），而且临床试验过程中难免会使用其他神药的干扰（毕竟受试者对安慰剂组的担忧和国人本能对输液的需求），再叠加各个中心主观评分的不一致性，脑保护临床试验阳性结果的难度可见一斑。在欧美等主流医学界对脑保护剂没有推荐之前，只能说是中国特色的存在。参考资料： Preclinical evaluation of ZL006-05, anew antistroke drug with fast-onset antidepressant and anxiolytic effects 《Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: aphase III, randomized, double-blind,comparative trial.》《Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial》推荐阅读

临床3期上市批准临床成功